

KPMG, Thermo Fisher to work on gene interaction with medicines

28 August 2019 | News

Heightened capability aimed at improving pharmacy safety, health outcomes with the use of genetic testing

KPMG's Care Continuum Optimization adds pharmacogenomic testing

From 140 million patient claims and 160 other data sources...

- Clinical and Operational Improvements
- Total Cost of Care Assessments
- Quality Measure Gains
- Heightened Operational Flow

KPMG CORIELL LIFE SCIENCES ThermoFisher SCIENTIFIC

KPMG's Clinical Intelligence (KCI) platform is helping clinicians improve the quality of care by furnishing them with pharmacogenomics data – information about how genes interact with medicines – from Coriell Life Sciences (CLS), supported by Thermo Fisher Scientific's leading genetic analysis platform and content.

Clinicians will use CLS' industry-leading Enterprise PGx (EPGx) program with data from Thermo Fisher platforms and trained pharmacists will assess genetic-based risks associated with a patient's medicines.

EPGx leverages genetic information with traditional medication therapy management that alerts prescribers to risks and provides medication options that can improve safety and efficacy.

The results are included in the patient's electronic health record. KPMG's Care Continuum Optimization, a program under KCI that aims to reduce the variability of treatment, can put information in clinicians' hands to help them develop a treatment plan aimed at improving quality measures. The data gathered also has utility for population health management and managed healthcare organizations.